Cure-NK

Cure-NK is a South Korean biotechnology company specializing in the development of next-generation natural killer (NK) cell therapies for the treatment of refractory cancers. The company utilizes a proprietary platform for the high-purity expansion and potent activation of NK cells derived from healthy donors or umbilical cord blood. Their lead programs focus on enhancing the infiltration and persistence of NK cells within the immunosuppressive microenvironment of solid tumors. By leveraging advanced cell engineering and cytokine-based activation, Cure-NK aims to provide off-the-shelf immunotherapy solutions that overcome the limitations of current T-cell based treatments.